Supernus Pharmaceuticals, Inc. (SUPN) Q1 2014 Earnings Results

Supernus Pharmaceuticals Misses on Revenue, Stock Down 2.07%

Supernus Pharmaceuticals reported a loss per share of $-0.38, which was better than expected, resulting in a 14.22% surprise on EPS. However, the stock reacted negatively, dropping 2.07%. The lack of revenue data and guidance may have contributed to investor concerns.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.38	N/A	+14.22%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

Supernus Pharmaceuticals Misses on Revenue, Stock Down 2.07%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Misses on Revenue, Stock Down 2.07%

Key numbers

Management commentary